Categories Earnings, LATEST, Technology

Intel’s (INTC) Q4 results beat estimates

Intel Corp. (NASDAQ: INTC) topped revenue and earnings estimates for the fourth quarter of 2019, sending shares soaring 6.8% in aftermarket hours on Thursday.

Total revenue grew 8% year-over-year to $20.2 billion, beating forecasts of $19.2 billion.  

Intel topped Q4 2019 revenue and earnings estimates

GAAP net income increased 33% to $6.9 billion and EPS rose 40% to $1.58. Adjusted net income rose 13% to $6.7 billion while adjusted EPS grew 19% to $1.52. Analysts had estimated adjusted EPS of $1.25.

During the quarter, revenues in the DCG segment increased 19%, aided by strong demand from cloud service provider customers and a strong mix of high-performance 2nd-Generation Intel Xeon Scalable processors. Revenues in the IOTG division improved 13% helped by momentum in retail and transportation.

Mobileye revenues jumped 31% year-over-year due to an increase in ADAS adoption. Revenues in NSG was up 10% due to NAND and Intel Optane bit growth. PSG revenue fell 17% year-over-year. Revenues in the CCG segment increased 2% helped by higher modem sales and desktop platform volumes.

For the first quarter of 2020, Intel expects revenue of approx. $19 billion. GAAP EPS is expected to be $1.23 while adjusted EPS is expected to be $1.30. Revenue is expected to be approx. $73.5 billion for the full year of 2020. EPS, on a GAAP basis, is estimated to be $4.71 and, on an adjusted basis, is projected to be $5.00.  

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

HP Inc. (HPQ) stock research summary | Q3 2021

HP Inc has shown a strong performance in Q4 2021. In spite of remote working, HP has shown a strong demand for PC and printer. The company has beat Zacks

VMware Inc. (VMW) stock research summary | Q3 2021

In this era of digital transformation, the technology industry is seeing a rapid influx of innovative products and solutions that help businesses adapt to the fast-changing and complex environment. VMware

IPO Alert: Cancer drug company Nuvectis Pharma set for $30-million IPO

After months of hectic activity, the IPO market experienced a lull in the Thanksgiving week, but it is still headed for a record year though the rush led by the

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top